Fortis Healthcare Limited
Tower A, Unitech Business Park, Block - F,
South City 1, Sector - 41, Gurgaon,
Haryana - 122001 (India)
Tel : 0124 492 1061
Fax : 0124 492 1041
Emergency : 105010
E-mail : contactus@fortishealthcare.com
Website : www.fortishealthcare.com

FHL/SEC/STEX/RR/2012-13
June 12, 2012

The National Stock Exchange of India Ltd.
Corporate Communications Department
"Exchange Plaza", 5th Floor,
Bandra-Kurla Complex, Bandra (East),
Mumbai - 400051
Scrip Symbol: FORTIS

Bombay Stock Exchange Limited
Corporate Services Department
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

Scrip Code:532843

Sub: Press Release

Dear Sir(s),

Please take note that today, Fortis Healthcare Limited (Company) has entered into "Definitive Agreements" approving investment of Rs. 370 Cr. by International Finance Corporation ("IFC") and NYLIM Jacob Ballas India Fund III LLC ("NJBIF") whereunder IFC and NJBIF have agreed to make investment of Rs. 120 Crores and Rs. 250 Crores, respectively in Super Religare Laboratories Limited, a subsidiary of the Company, in form of Compulsorily Convertible Preference Shares.

A copy of Press Release to be issued by the Company with respect to above is attached herewith for your reference and record.

Thanking you,

Yours faithfully,
For Fortis Healthcare Limited

FORTIS HEALTHCARE LTD. NEW DELHI

Rahul Ranjan
Company Secretary

Encl: As above

Press Release

Fortis to get Rs 3700 Mn Equity infusion in SRL through IFC and NYLIM Jacob Ballas India

New Delhi, June 12, 2012: Fortis Healthcare Limited ("FHL"), one of the largest healthcare chains in Asia Pacific, today, announced that its diagnostic chain subsidiary Super Religare Laboratories ("SRL" or "Company") has signed definitive agreements with high quality investment partners, NYLIM Jacob Ballas India Fund III LLC, Mauritius ("NJBIF") and International Finance Corporation ("IFC") for an equity investment in the Company. NJBIF and IFC will invest Rs 2,500 million and Rs 1,200 million respectively in SRL in the form of Compulsorily Convertible Preference Shares ("CCPS"). The conversion of CCPS will be in the price band of Rs 201-Rs 220. Post conversion of CCPS, FHL will continue to hold 55-56% equity stake in SRL. The transaction will be subject to customary closing conditions and is expected to take place within this month itself.

As of March 31, 2012, SRL had a network, either directly owned by it or operated through franchisees or joint ventures, consisting of 8 reference laboratories, 8 Centres of Excellence, 208 network laboratories, 21 wellness centres and over 1088 collection centres (including 32 abroad). SRL has already made a significant outlay to enhance its diagnostics capability and reach, in India. Besides retiring a substantial part of the debt to deleverage the company, the proceeds of the investment will be used to consolidate and grow the existing network of SRL. This will be the third round of private equity investment in the Company, after Avigo Capital Partners and Sabre Partners, invested Rs 1,500 million in the Company, in 2011.

Commenting on this development, **Mr. Vishal Bali, Group CEO, Fortis Healthcare Limited** said: "We are delighted to have Jacob Ballas and IFC as investment partners in SRL, their interest exhibits the potential of the company as a market leader in Diagnostics. We see immense opportunity for growth in the Diagnostics vertical both in India and other regions of Asia. This investment will go towards our consolidation strategy to improve market share and create sector leadership. The deal is a testimony to our commitment to provide quality and cutting edge diagnostic services to our customers in India and around the world and fortifies our resolve to be the leading diagnostic services company in the country."

Mr. Srinivas Chidambaram, Managing Director, Jacob Ballas Capital India Private Limited, investment advisor to NJBIF, commented: "We are pleased to assist the leading management team in the diagnostic services sector in realizing their vision to address the significant pan-India and regional potential in a historically "un-organized" industry, with an emphasis on quality, reliability and service. Having made significant investments in world class diagnostics infrastructure, a team of well qualified healthcare professionals and modern diagnostic techniques, SRL is ideally positioned to benefit patients, healthcare institutions and doctors nationwide."

Certified True Copy
For Fortis Healthcare Limited
Company Secretary

"IFC is partnering with Super Religare Laboratories to help the company expand its existing network of laboratories across India," said, **Thomas Davenport, Director for South Asia, IFC.** "This will help provide advanced, high quality diagnostics services especially in several low income states of India, which is a key priority for IFC," he added.

About SRL Ltd –www.srlworld.com

Super Religare Laboratories (SRL), one of the leading diagnostic services companies in India, offers diagnostic testing (including pathology and radiology), preventive care testing and clinical research trial testing. As of March 31, 2012, SRL had a network, either directly owned by it or operated through franchisees or joint ventures, consisting of 8 reference laboratories, 8 Centres of Excellence, 208 network laboratories, 21 wellness centres and over 1088 collection centres (including 32 abroad). During the year ended March 31, 2012, SRL served over 8.60 million customers and performed over 56,000 diagnostic tests per day. It provides routine (hematology and chemistry), specialized (histopathology, immunohistochemistry and cytogenetic) and esoteric tests (molecular assays and flow cytometry).

About Fortis Healthcare- www.fortishealthcare.com

Fortis Healthcare Limited is a leading, integrated healthcare delivery provider in the Pan Asia-Pacific region. The healthcare verticals of the company span primary healthcare, speciality day care, diagnostics and hospitals, with an asset base in 10 countries, many of which represent the fastest-growing healthcare delivery markets in the world. Currently, the company operates its healthcare delivery network in Australia, Canada, Dubai, Hong Kong, India, Mauritius, New Zealand, Singapore, Sri Lanka and Vietnam with 75 hospitals, over 12,000 beds, over 600 primary care centres, 191 day care speciality centres, over 210 diagnostic centres and a talent pool of over 23,000 people. Fortis Healthcare is driven by the vision of becoming a global leader in the integrated healthcare delivery space and the larger purpose of saving and enriching lives through clinical excellence.

About Jacob Ballas Capital and NYLIM Jacob Ballas Funds

Jacob Ballas Capital India Private Limited ("JBC", www.jbindia.co.in) is a leading private equity advisor based in New Delhi, India with a 19 member team, advising three India focused Mauritius based private equity funds ("NYLIM Jacob Ballas Funds" or the "Funds") with funds under management of over $600 million. The Funds have completed twenty five growth capital investments in India since 2000, typically in privately held, growth oriented "blue-chip" Indian companies, usually leadership platforms in diverse sectors including telecom, ports, power, engineering construction, shipbuilding, IT services, life sciences, financial services and general manufacturing. JBC has a strong track record of assisting portfolio companies in business strategy, business development, strategic alliances, talent attraction, M&A initiatives, and IPO preparation.

About IFC

FORTIS HEALTHCARE LTD. NEW DELHI

IFC, a member of the World Bank Group is the largest global development institution focused exclusively on the private sector. We help developing countries achieve sustainable growth by financing investment, providing advisory services to businesses and governments, and mobilizing capital in the international financial markets. In fiscal 2011, amid economic uncertainty across the globe, we helped our clients create jobs, strengthen environmental performance, and contribute to their local communities—all while driving our investments to an all-time high of nearly $19 billion. For more information, visit www.ifc.org.

For further information, please contact:

Raghu Kochar / Ruhee Dhar

Fortis Healthcare Limited

+91- 9811617256 / +91-9818102377

Anurag Kalra / Gaurav Chugh

Fortis Healthcare Limited

+91-9810109253 / +91-9958588900

DISCLAIMER

This press release may contain forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this press release are cautioned not to place undue reliance on these forward-looking statements. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this press release, without obligation to notify any person of such revision or changes.

FORTIS HEALTHCARE LTD. NEW DELHI